Skip to main content

Table 1 Overall survival rates and cumulative incidences of mortality among patients with advanced ECCA

From: Prognostic model for oversurvival and tumor-specific survival prediction in patients with advanced extrahepatic cholangiocarcinoma: a population-based analysis

Characteristic

 

Patients

Overall Survival rate(%)

P

Cancer-special mortality(%)

P

Non-cancer-special mortality(%)

P

No.

%

1 year

2 year

3 year

 

1 year

2 year

3 year

 

1 year

2 year

3 year

Total

 

403

100.0

31.3

12.0

7.0

 

58.7

74.2

78.0

 

10.0

13.8

15.0

 

Age (years)

< 65

167

41.4

40.1

15.8

10.8

0.014

52.0

72.1

75.8

0.447

7.9

12.1

13.3

0.744

≥65

236

58.6

25.1

9.4

4.3

 

63.4

75.7

79.6

 

11.5

14.9

16.2

 

Sex

Female

192

47.6

29.4

8.9

4.7

0.130

61.7

78.5

81.7

0.143

8.9

12.6

13.6

0.594

Male

211

52.4

33.1

14.9

9.0

 

55.9

70.3

74.7

 

11.0

14.8

16.3

 

Race

Black

32

7.9

18.8

6.3

3.1

0.060

68.8

75.0

75.0

0.877

12.5

18.8

21.9

0.353

White

371

92.1

32.4

12.5

7.3

 

57.8

74.2

78.3

 

9.8

13.3

14.4

 

T

T0

5

1.2

20.0

20.0

20.0

0.041

80.0

80.0

80.0

0.232

0.0

0.0

0.0

0.795

T1

91

22.6

17.8

5.6

3.3

 

71.1

77.7

80.0

 

11.1

16.7

16.7

 

T2

107

26.6

31.2

13.2

8.2

 

60.3

74.5

79.5

 

8.5

12.3

12.3

 

T3

92

22.8

37.5

18.7

11.0

 

57.1

71.4

74.7

 

5.5

9.9

14.3

 

T4

108

26.8

38.0

10.2

4.6

 

47.2

73.1

77.8

 

14.8

16.7

17.6

 

N

N0

196

48.6

25.3

9.3

4.7

0.005

65.4

78.3

81.4

0.062

9.3

12.4

13.9

0.761

N1

181

44.9

38.9

16.1

9.9

 

50.5

69.4

74.6

 

10.6

14.1

15.6

 

N2

26

6.5

23.1

3.9

3.9

 

65.4

76.9

76.9

 

11.5

19.2

19.2

 

M

M0

196

48.6

47.4

20.9

12.6

< 0.001

39.8

63.3

70.5

< 0.001

12.8

15.8

16.9

0.353

M1

207

51.4

15.8

3.5

1.5

 

76.9

84.8

85.3

 

7.4

11.8

13.3

 

Stage

III

133

33.0

51.1

24.8

15.6

< 0.001

37.6

61.7

70.1

< 0.001

11.3

13.5

14.3

0.837

IV

270

67.0

21.4

5.6

2.6

 

69.2

80.5

82.0

 

9.4

13.9

15.4

 

Surgical

No

311

77.2

20.2

5.9

3.3

< 0.001

68.8

81.1

82.5

< 0.001

11.0

13.0

14.3

0.248

Yes

92

22.8

68.5

32.6

19.3

 

25.0

51.1

63.3

 

6.5

16.3

17.4

 

Grade

I

55

13.6

16.4

5.5

1.8

0.046

76.4

85.5

87.3

0.022

7.3

9.1

10.9

0.477

II

179

44.4

34.8

13.7

8.0

 

55.0

71.5

76.6

 

10.2

14.8

15.3

 

III

165

40.9

32.7

12.1

7.1

 

56.4

73.3

76.5

 

10.9

14.5

16.4

 

IV

4

1.0

25.0

25.0

25.0

 

75.0

75.0

75.0

 

–

–

–

 

Year of diagnosis

2000–2009

32

7.9

43.8

9.4

0.0

0.770

25.0

43.8

–

< 0.001

31.3

46.9

–

< 0.001

2010–2017

371

92.1

30.2

12.3

7.6

 

61.6

76.9

81.0

 

8.1

10.9

11.4

 

Radiation

No

294

73.0

31.0

12.4

7.9

< 0.001

59.4

74.9

78.3

0.507

9.6

12.7

13.7

0.359

Yes

109

27.0

32.1

11.0

4.3

 

56.9

72.5

77.2

 

11.0

16.5

18.5

 

Chemtherapy

No

223

55.3

28.7

9.1

5.5

0.150

60.8

77.7

80.4

0.198

10.5

13.2

14.1

0.592

Yes

180

44.7

34.4

15.6

8.8

 

56.1

70.0

75.1

 

9.4

14.4

16.1

 

Diagnostic Confirmation

Clinical diagnosis only

3

0.7

33.3

0.0

0.0

0.100

66.7

–

–

0.483

0.0

–

–

0.949

Direct visualization without microscopic confirmation

1

0.2

0.0

0.0

0.0

 

–

–

–

 

–

–

–

 

Positive exfoliative cytology, no positive histology

86

21.3

23.3

5.8

3.5

 

65.1

79.1

81.4

 

11.6

15.1

15.1

 

Positive histology

294

73.0

33.7

13.8

7.8

 

57.0

72.8

77.0

 

9.3

13.4

15.1

 

Radiography without microscopic confirm

19

4.7

31.6

15.8

10.5

 

52.6

68.4

73.7

 

15.8

15.8

15.8

 
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us